Patents by Inventor Shigero Tamba
Shigero Tamba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912989Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: GrantFiled: February 23, 2021Date of Patent: February 27, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Patent number: 11827699Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: GrantFiled: July 5, 2018Date of Patent: November 28, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu
-
Publication number: 20230279099Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: April 25, 2023Publication date: September 7, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Patent number: 11673947Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: GrantFiled: August 13, 2019Date of Patent: June 13, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20220324966Abstract: Disclosed are an antigen-binding molecule containing a sugar chain receptor-binding domain and having a weak antigen-binding activity in the pH of early-stage endosome compared to the antigen-binding activity in the pH of plasma; a pharmaceutical composition containing the antigen-binding molecule; and a method for producing these. Use of the antigen-binding molecule of the invention enables to promote uptake of an antigen into a cell and increase the number of antigens that a single antibody molecule can bind. Administration of the antibody enables to reduce the number of antigens in plasma more and more and improve pharmacokinetics of the antibody.Type: ApplicationFiled: April 8, 2022Publication date: October 13, 2022Inventors: Tomoyuki IGAWA, Shigero TAMBA, Meiri KAWAZOE
-
Publication number: 20210180049Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: ApplicationFiled: February 23, 2021Publication date: June 17, 2021Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Patent number: 10961530Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: GrantFiled: December 4, 2014Date of Patent: March 30, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Publication number: 20190359704Abstract: The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: August 13, 2019Publication date: November 28, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20190185557Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn wider an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: ApplicationFiled: July 5, 2018Publication date: June 20, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu
-
Publication number: 20170129950Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cells.Type: ApplicationFiled: September 15, 2016Publication date: May 11, 2017Inventors: Hirotake SHIRAIWA, Keiko Esaki, Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Shigero Tamba, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Yasuko Kinoshita, Masami Suzuki, Atsuhiko Kato, Etsuko Takeiri, Eri Hashimoto, Yoshinori Watanabe
-
Patent number: 9556264Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.Type: GrantFiled: December 28, 2012Date of Patent: January 31, 2017Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hirotake Shiraiwa, Keiko Esaki, Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Shigero Tamba, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Yasuko Kinoshita, Masami Suzuki, Atsuhiko Kato, Etsuko Takeiri, Eri Hashimoto, Yoshinori Watanabe
-
Publication number: 20170022270Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: ApplicationFiled: August 8, 2016Publication date: January 26, 2017Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu
-
Publication number: 20160304862Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: ApplicationFiled: December 4, 2014Publication date: October 20, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki IGAWA, Shigero TAMBA, Shun SHIMIZU, Kanako TATSUMI, Shojiro KADONO, Hiroki KAWAUCHI, Kazuhiro OHARA, Masayuki MATSUSHITA, Takashi EMURA, Masaki KAMIMURA
-
Publication number: 20150299313Abstract: Disclosed are an antigen-binding molecule containing a sugar chain receptor-binding domain and having a weak antigen-binding activity in the pH of early-stage endosome compared to the antigen-binding activity in the pH of plasma; a pharmaceutical composition containing the antigen-binding molecule; and a method for producing these. Use of the antigen-binding molecule of the invention enables to promote uptake of an antigen into a cell and increase the number of antigens that a single antibody molecule can bind. Administration of the antibody enables to reduce the number of antigens in plasma more and more and improve pharmacokinetics of the antibody.Type: ApplicationFiled: October 5, 2012Publication date: October 22, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Shigero Tamba, Meiri Kawazoe
-
Publication number: 20150166654Abstract: The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: May 30, 2013Publication date: June 18, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20150110793Abstract: The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.Type: ApplicationFiled: December 28, 2012Publication date: April 23, 2015Inventors: Hirotake Shiraiwa, Keiko Esaki, Tomoyuki Igawa, Taichi Kuramochi, Atsuhiko Maeda, Shigero Tamba, Hiroyuki Tsunoda, Tatsuhiko Tachibana, Yasuko Kinoshita, Masami Suzuki, Atsuhiko Kato, Etsuko Takeiri, Eri Hashimoto, Yoshinori Watanabe
-
Publication number: 20150050269Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: ApplicationFiled: September 28, 2012Publication date: February 19, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu